Lataa...
Erlotinib treatment induces cytochrome P450 3A activity in non‐small cell lung cancer patients
AIMS: Erlotinib is a tyrosine kinase inhibitor used in the treatment of non‐small cell lung cancer highly metabolized by the cytochrome P450 (CYP) 3A. Hence, CYP3A4 activity might be a useful predictor of erlotinib pharmacokinetics in personalized medicine. The effect of erlotinib on CYP3A activity...
Tallennettuna:
| Julkaisussa: | Br J Clin Pharmacol |
|---|---|
| Päätekijät: | , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
John Wiley and Sons Inc.
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6624433/ https://ncbi.nlm.nih.gov/pubmed/30945322 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13953 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|